EGFR and non-small cell lung carcinoma: Previous studies have reported that antigen expression and presentation deficiency, the low mutation burden, immunosuppressive microenvironment, and upregulation of PD-L1 may be the mechanisms that limited efficacy of ICIs in EGFR mutant NSCLC patients (2, 20–23).